Registered title, quoted from ClinicalTrials.gov
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Henan Cancer Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06774222, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed resectable or potentially resectable locally advanced gastric/gastroesophageal junction adenocarcinoma;
Inclusion criterion 3
Tumor Regression Grade (TRG) 2 or 3 after preoperative adjuvant therapy;
Inclusion criterion 4
R0 resection after neoadjuvant chemotherapy;
Inclusion criterion 5
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
Inclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06774222, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Fully understand the study and voluntarily sign the informed consent form;
- Age between 18 and 75 years;
- Histologically confirmed resectable or potentially resectable locally advanced gastric/gastroesophageal junction adenocarcinoma;
- Tumor Regression Grade (TRG) 2 or 3 after preoperative adjuvant therapy;
- R0 resection after neoadjuvant chemotherapy;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- Life expectancy of at least 2 years;
- No prior anti-cancer treatment received;
- Good compliance and cooperation with follow-up.
Exclusion Criteria:
- Inability to comply with the study protocol or procedures;
- History of prior gastric cancer surgery;
- Contraindications to surgical treatment and chemotherapy or physical condition and organ function that do not allow for major abdominal surgery;
- Distant metastasis to organs other than the liver, such as lung, brain, and bone;
- Known HER2-positive patients;
- Uncontrolled hypertension despite medication prior to enrollment;
- Poorly controlled diabetes despite medication prior to enrollment;
- Urine routine indicating proteinuria ≥2+, and a 24-hour urine protein quantification >1.0g;
- Presence of conditions requiring intervention such as bleeding, perforation, or obstruction prior to enrollment;
- Patients deemed ineligible for this study by the investigator.
Quoted from ClinicalTrials.gov, NCT06774222, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06774222, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.